REPL Replimune Group Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: REPL

Price (delayed)

$18.99

Market cap

$1.1B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.99

Enterprise value

$1.01B

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary ...

Highlights
The company's equity rose by 35% YoY but it fell by 7% QoQ
Replimune Group's debt has soared by 85% YoY
The net income has contracted by 48% YoY and by 11% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.replimune.com
Peers: OVID

Key stats

What are the main financial stats of REPL
Market
Shares outstanding
57.78M
Market cap
$1.1B
Enterprise value
$1.01B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.94
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$169.84M
EBITDA
-$167.39M
Free cash flow
-$130.32M
Per share
EPS
-$2.99
Free cash flow per share
-$2.24
Book value per share
$9.8
Revenue per share
$0
TBVPS
$11.11
Balance sheet
Total assets
$646.59M
Total liabilities
$91.3M
Debt
$60.76M
Equity
$555.29M
Working capital
$558.78M
Liquidity
Debt to equity
0.11
Current ratio
17.52
Quick ratio
17.38
Net debt/EBITDA
0.52
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-31.4%
Return on equity
-35.8%
Return on invested capital
-39%
Return on capital employed
-27.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

REPL stock price

How has the Replimune Group stock price performed over time
Intraday
2.76%
1 week
-2.57%
1 month
9.58%
1 year
24.77%
YTD
-30.18%
QTD
7.53%

Financial performance

How have Replimune Group's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$177.08M
Net income
-$174.28M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 50% year-on-year and by 13% since the previous quarter
The net income has contracted by 48% YoY and by 11% from the previous quarter

Growth

What is Replimune Group's growth rate over time

Valuation

What is Replimune Group stock price valuation
P/E
N/A
P/B
1.94
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 32% YoY and by 4.5% QoQ
The company's equity rose by 35% YoY but it fell by 7% QoQ
REPL's price to book (P/B) is 31% lower than its 5-year quarterly average of 2.8 and 8% lower than its last 4 quarters average of 2.1

Efficiency

How efficient is Replimune Group business performance
REPL's ROE is down by 36% YoY and by 2.9% QoQ
Replimune Group's return on assets has decreased by 31% YoY
Replimune Group's return on invested capital has decreased by 21% YoY

Dividends

What is REPL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for REPL.

Financial health

How did Replimune Group financials performed over time
The total liabilities has surged by 83% year-on-year and by 10% since the previous quarter
The total assets is up by 40% YoY but it is down by 4.7% from the previous quarter
Replimune Group's debt is 89% less than its equity
Replimune Group's debt has soared by 85% YoY
The debt to equity has increased by 38% year-on-year and by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.